Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DAO | P14920 | 1/20 | 0.32 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.31 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.31 |
| ▸ | GPR3 | P46089 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29556373 | 1.00 | DAO (0.32) | DAOHDAC1HDAC6GPR3 | |
| SCHEMBL29955299 | 0.90 | DAO (0.32) | DAOHDAC1HDAC6GPR3 | |
| SCHEMBL2914323 | 0.90 | DAO (0.32) | DAOHDAC1HDAC6GPR3 | |
| SCHEMBL5301120 | 0.87 | ACHE (0.31) | — | |
| SCHEMBL28824845 | 0.87 | — | — | |
| SCHEMBL12156280 | 0.85 | DAO (0.32) | DAOHDAC1HDAC6GPR3 | |
| SCHEMBL14244142 | 0.82 | ACHE (0.31) | — | |
| SCHEMBL29957601 | 0.82 | ACHE (0.31) | — | |
| SCHEMBL29419677 | 0.81 | — | — | |
| SCHEMBL581257 | 0.81 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250388565-A1 | ESTROGEN RECEPTOR ALPHA DEGRADERS AND METHODS OF USE THEREOF | RELAY THERAPEUTICS, INC. | 2025-12-25 | — | — | US | disclosed |
| WO-2024006776-A1 | ESTROGEN RECEPTOR ALPHA DEGRADERS AND MEDICAL USE THEREOF | RELAY THERAPEUTICS, INC. (US) | 2024-01-04 | — | — | WO | disclosed |
| CN-108689924-B | 4-amino-6- (4-substituted phenyl) -pyridine-2-carboxylic acid esters and their use as herbicides | 美国陶氏益农公司 | 2022-04-12 | — | — | CN | disclosed |
| EP-3440938-A1 | 4-AMINO-6-(4-SUBSTITUTED-PHENYL)-PICOLINATES AND THEIR USE AS HERBICIDES | Dow AgroSciences LLC (US) | 2019-02-13 | — | — | EP | disclosed |
| EP-3440938-A1 | 4-AMINO-6-(4-SUBSTITUTED-PHENYL)-PICOLINATES AND THEIR USE AS HERBICIDES | Dow AgroSciences LLC (US) | 2019-02-13 | — | — | EP | disclosed |
| EP-2967069-B1 | 4-AMINO-6-(4-SUBSTITUTED-PHENYL)-PICOLINATES AND 6-AMINO-2-(4-SUBSTITUTED-PHENYL)-PYRIMIDINE-4-CARBOXYLATES AND THEIR USE AS HERBICIDES | DOW AGROSCIENCES LLC (US) | 2018-10-24 | — | — | EP | disclosed |
| US-9475811-B2 | 1-aza-bicyclo[3.3.1]nonanes | NOVARTIS AG (CH) | 2016-10-25 | — | — | US | disclosed |
| EP-2967069-A1 | 4-AMINO-6-(4-SUBSTITUTED-PHENYL)-PICOLINATES AND 6-AMINO-2-(4-SUBSTITUTED-PHENYL)-PYRIMIDINE-4-CARBOXYLATES AND THEIR USE AS HERBICIDES | Dow AgroSciences LLC (US) | 2016-01-20 | — | — | EP | disclosed |
| US-9113629-B2 | 4-amino-6-(4-substituted-phenyl)-picolinates and 6-amino-2-(4-substituted-phenyl)-pyrimidine-4-carboxylates and their use as herbicides | DOW AGROSCIENCES LLC (US) | 2015-08-25 | — | — | US | disclosed |
| US-9113629-B2 | 4-amino-6-(4-substituted-phenyl)-picolinates and 6-amino-2-(4-substituted-phenyl)-pyrimidine-4-carboxylates and their use as herbicides | DOW AGROSCIENCES LLC (US) | 2015-08-25 | — | — | US | disclosed |
| US-20140274696-A1 | 4-AMINO-6-(4-SUBSTITUTED-PHENYL)-PICOLINATES AND 6-AMINO-2-(4-SUBSTITUTED-PHENYL)-PYRIMIDINE-4-CARBOXYLATES AND THEIR USE AS HERBICIDES | DOW AGROSCIENCES LLC (US) | 2014-09-18 | — | — | US | disclosed |
| US-20140274696-A1 | 4-AMINO-6-(4-SUBSTITUTED-PHENYL)-PICOLINATES AND 6-AMINO-2-(4-SUBSTITUTED-PHENYL)-PYRIMIDINE-4-CARBOXYLATES AND THEIR USE AS HERBICIDES | DOW AGROSCIENCES LLC (US) | 2014-09-18 | — | — | US | disclosed |
| US-20140274696-A1 | 4-AMINO-6-(4-SUBSTITUTED-PHENYL)-PICOLINATES AND 6-AMINO-2-(4-SUBSTITUTED-PHENYL)-PYRIMIDINE-4-CARBOXYLATES AND THEIR USE AS HERBICIDES | DOW AGROSCIENCES LLC (US) | 2014-09-18 | — | — | US | disclosed |
| EP-1761533-B8 | 1-AZA-BICYCLO[3.3.1]NONANES | NOVARTIS AG (CH) | 2011-10-12 | — | — | EP | disclosed |
| EP-2336129-A1 | 1-aza-bicyclo[3.3.1]nonanes | Novartis AG (CH) | 2011-06-22 | — | — | EP | disclosed |
| EP-1761533-B1 | 1-AZA-BICYCLO[3.3.1]NONANES | NOVARTIS AG (CH) | 2011-04-20 | — | — | EP | disclosed |
| US-20110034475-A1 | 1-AZA-BICYCLO[3.3.1]NONANES | NOVARTIS AG | 2011-02-10 | — | — | US | disclosed |
| US-20070249657-A1 | 1-Aza-Bicyclo3.3.1Nonanes | NOVARTIS AG (CH) | 2007-10-25 | — | — | US | disclosed |
| EP-1761533-A1 | 1-AZA-BICYCLO[3.3.1]NONANES | Novartis AG (CH) | 2007-03-14 | — | — | EP | disclosed |
| WO-2005123732-A1 | 1-AZA-BICYCLO[3.3.1]NONANES | NOVARTIS AG (CH) | 2005-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250388565-A1 | ESTROGEN RECEPTOR ALPHA DEGRADERS AND METHODS OF USE THEREOF | ESRRA, ESRRB, ESR2 | DAO 1668/4885HDAC1 1515/4885HDAC6 2968/4885 |
| US-20140274696-A1 | 4-AMINO-6-(4-SUBSTITUTED-PHENYL)-PICOLINATES AND 6-AMINO-2-(4-SUBSTITUTED-PHENYL)-PYRIMIDINE-4-CARBOXYLATES AND THEIR USE AS HERBICIDES | DDT, P2RX6, ABAT | DAO 52/4885HDAC1 3203/4885HDAC6 2833/4885 |
| US-20070249657-A1 | 1-Aza-Bicyclo3.3.1Nonanes | CBR3, CBR1, HCAR3 | DAO 866/4885HDAC1 69/4885HDAC6 317/4885 |
| US-20110034475-A1 | 1-AZA-BICYCLO[3.3.1]NONANES | CBR3, CBR1, HRH4 | DAO 904/4885HDAC1 131/4885HDAC6 550/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.